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Abstract: The aggregation and deposition of α-synuclein (αS) are major pathologic features of
Parkinson’s disease, dementia with Lewy bodies, and other α-synucleinopathies. The propagation of
αS pathology in the brain plays a key role in the onset and progression of clinical phenotypes. Thus,
there is increasing interest in developing strategies that attenuate αS aggregation and propagation.
Based on cumulative evidence that αS oligomers are neurotoxic and critical species in the pathogenesis
ofα-synucleinopathies, we and other groups reported that phenolic compounds inhibitαS aggregation
including oligomerization, thereby ameliorating αS oligomer-induced cellular and synaptic toxicities.
Heterogeneity in gut microbiota may influence the efficacy of dietary polyphenol metabolism.
Our recent studies on the brain-penetrating polyphenolic acids 3-hydroxybenzoic acid (3-HBA),
3,4-dihydroxybenzoic acid (3,4-diHBA), and 3-hydroxyphenylacetic acid (3-HPPA), which are derived
from gut microbiota-based metabolism of dietary polyphenols, demonstrated an in vitro ability to
inhibit αS oligomerization and mediate aggregated αS-induced neurotoxicity. Additionally, 3-HPPA,
3,4-diHBA, 3-HBA, and 4-hydroxybenzoic acid significantly attenuated intracellular αS seeding
aggregation in a cell-based system. This review focuses on recent research developments regarding
neuroprotective properties, especially anti-αS aggregation effects, of phenolic compounds and their
metabolites by the gut microbiome, including our findings in the pathogenesis of α-synucleinopathies.
Keywords: Parkinson’s disease; α-synuclein; phenolic compounds; gut microbiome
1. Introduction
Parkinson’s disease (PD) is the most common type of parkinsonism, a term reflecting a group of
neurological disorders that cause PD–like movement problems such as rigidity, slowness, and tremor.
More than six million individuals worldwide have PD [1]. The disease is characterized by the death
of dopaminergic neurons in the substantia nigra. The pathologic hallmark of PD is the Lewy body
(LB), a neuronal inclusion consisting largely of α-synuclein (αS) protein aggregations, which are
associated with the death of dopamine-producing cells. The most widely cited model for explaining
the neuropathological progression of PD is the Braak hypothesis [2]. LB pathology starts (stages 1 and
2) in the medulla and the olfactory bulb. This early pathology is associated with symptoms that occur
before the onset of movement difficulties. These early symptoms include rapid eye movement sleep
behavior disorder and decreased smell. In stages 3 and 4, the pathology progresses to the substantia
nigra pars compacta and other midbrain and basal forebrain structures. Pathology in these areas is
associated with classic motor symptoms, and, typically, PD is diagnosed at this stage. In advanced
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PD, the pathology progresses to the cerebral cortices and is concomitant with the onset of cognitive
impairment and hallucinations [2].
In rare cases, autosomal dominant PD is caused by missense variants (A53T, A30P, and E46K) [3–5]
and the overexpression of αS [6,7]. Currently, the supplementation of dopamine is the mainstay of PD
treatment, since, to date, no means to modify αS aggregation have been identified [1]. Dementia with
Lewy bodies (DLB) is a slowly progressive and persistent dementia disorder of the elderly, clinically
characterized by fluctuating attention, recurrent visual hallucinations, and parkinsonism [8,9]. As with
PD, LBs and Lewy neurites in the brain constitute the main histopathological features of DLB.
Multiple system atrophy (MSA) is a neurodegenerative disease characterized by progressive
autonomic failure, parkinsonism, and cerebellar and pyramidal tract symptoms. Glial cytoplasmic
inclusions of αS are a defining histologic feature of this disease, and there is no curative treatment [10].
An in vivo study in mice demonstrated that the overexpression of αS in oligodendrocytes results in
MSA-like degeneration in the central nervous system [11]. Taken together with biochemical and genetic
evidence, the aggregation of αS may play an important role in the development of α-synucleinopathies,
including PD, DLB, and MSA.
αS tend to fold and aggregate to form oligomers, protofibrils, and mature fibrils; it has been
suggested that these cause neuronal dysfunction in the pathogenesis of α-synucleinopathies [12,13].
Although the internal origin of αS toxicity remains unclear, accumulating evidence suggests that it
may be the oligomeric forms of αS, rather than the larger intracellular inclusions (mature fibrils), that
are the most bioactive and, possibly, cytotoxic, causing not only neuronal dysfunction but also cell
death [14–17].
Dietary intake of polyphenols may be associated with PD risk. A large prospective study
conducted over two decades involving almost 130,000 individuals showed that the habitual intake
of polyphenols and polyphenol-rich foods such as berry fruits may reduce the risk of developing
PD, and the association is more pronounced in men than in women [18]. Previous epidemiological
studies have detailed an inverse relationship between green/black tea consumption and the risk of
developing PD [19–23]. Moreover, a meta-analysis of tea drinkers and non-drinkers showed that tea
drinking offers protective effects against the risk being affected by PD [24]. The protective effects have
been attributed to the antioxidant and anti-inflammatory properties of these foodstuffs [25]. Evidence
from in vitro and in vivo studies has further indicated that polyphenols such as (–)-epigallocatechin
gallate (EGCG) in green tea, curcuminoids in curry, baicalein extracted from the root of Scutellaria
baicalensis, a traditional Chinese herb, or extracts from grape and blueberry protect against neuronal
damage in PD [26,27]. Levites et al. reported that EGCG shows neuroprotective properties against
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism in animal models because
of the iron-chelating and free radical scavenging activities of the cathecol group [28,29]. Polyphenols
also have protective effects against αS toxicity [30,31]. In experiments involving cell models of PD,
curcumin (Cur) was shown to reduce αS-induced cytotoxicity by decreasing intracellular reactive
oxygen species (ROS), mitochondrial depolarization, cytochrome c release, and caspase-9 and caspase-3
activation [30], or by downregulating mTOR (mammalian target of rapamycin)/p70S6K signaling and
recovering macroautophagy [31] (Figure 1).
Previously, we demonstrated that phenolic compounds such as myricetin (Myr), Cur, rosmarinic
acid (RA), nordihydroguaiaretic acid (NDGA), and ferulic acid (FA) inhibit the formation of αS fibrils
and destabilize preformed fibrils [27]. Similarly, it was reported that baicalein [32] and EGCG also inhibit
αS fibrillization and destabilize preformed fibrils [33,34]. Later, we revealed that Myr and RA hinder αS
oligomerization and secondary structure conversion, thus ameliorating αS synaptic toxicity. Similarly,
it has been reported that EGCG exerts protective effects against αS oligomer-induced membrane
disruption and cytotoxicity by facilitating fibril formation and eliminating toxic αS oligomers [35].
These results suggest that phenolic compounds prevent the occurrence of αS aggregation, thereby
reducing the neurotoxicity of αS oligomers.
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A number of studies have reported the presence of gut microbiota dysbiosis in patients with
PD, suggesting that this is a risk factor for developing the illness [36–38]. Moreover, recent
preclinical observations have supported a causal relationship between gut microbiota dysbiosis
and PD pathophysiology [39–41]. Notably, phenolic compounds modulate the gut–brain axis, which
transforms them into neuroprotective compounds through gut microbiome metabolism [42]. Recently,
we observed that interpersonal heterogeneity in gut microbiota may lead to interpersonal variabilities in
the efficacy with which dietary polyphenols are metabolized into select biologically available phenolic
metabolites [43]. We demonstrated that the brain-accumulating phenolic metabolites identified
in cecum specimens of gnotobiotic mice, namely, 3-(3′-hydroxyphenyl)propionic acid (3-HPPA),
3,4-dihydroxybenzoic acid (3,4-diHBA), 3-hydroxybenzoic acid (3-HBA), and 4-HBA, inhibit αS
oligomerization in vitro [43]. These phenolic acids also improved behavioral disturbances in a
Drosophila model of α-synucleinopathy [43]. Very recently, we determined not only that 3-HPPA,
3,4-diHBA, 3-HBA, and 4-HBA significantly attenuate intracellular αS seeding aggregation in a
cell-based system but also, using insoluble αS seeds extracted from post-mortem MSA or PD brain
specimens, 3-HPPA effectively attenuates the MSA-induced intracellular aggregation of αS [44].
This review focuses particularly on recent research developments regarding the neuroprotective
properties, especially the anti-αS aggregation effects, of phenolic compounds and the ability of
phenols and their metabolites to cross the blood–brain barrier. Our findings on the pathogenesis of
α-synucleinopathies are also included.
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(D,E) promoting the degradation of αS fibrils, (F) preventing the seeding and transfer of αS from cell 
to cell, (G) downregulating mTORC1 (mammalian target of rapamycin complex 1) signaling and 
recovering suppressed macroautophagy, and (H) reducing ROS (reactive oxygen species) 
generation. 
2. α-Synuclein Aggregation 
α-Synuclein tends to self-aggregate or cause the aggregation of other proteins. In vitro studies 
have shown both full-length wild-type (WT) and mutant αS molecules to be capable of 
self-aggregation into mature fibrils in a process that is dependent on time, temperature, pH, and 
concentration [45,46]. In these studies, the 10 nm-wide fibrils were noticeably twisted and bore a 
Figure 1. The main effects of natural phenolic compounds modulating αS aggregates. (A,B) Inhibiting
the oligomerization and fibrillization of αS, (C) preventing the accumulation of αS fibrils, (D,E)
promoting the degradation of αS fibrils, (F) preventing the seeding and transfer of αS from cell to cell,
(G) downregulating mTORC1 (mammalian target of rapamycin complex 1) signaling and recovering
suppressed macroautophagy, and (H) reducing ROS (reactive oxygen species) generation.
2. α-Synuclein Aggregation
α-Synuclein tends to self-aggregate or cause the aggregation of other proteins. In vitro studies
have shown both full-length wild-type (WT) and mutant αS molecules to be capable of self-aggregation
into mature fibrils in a process that is dependent on time, temperature, pH, and concentration [45,46].
In these studies, the 10 nm-wide fibrils were noticeably twisted and bore a close resemblance to
the fibrils isolated from both the LBs of patients with PD and DLB and the filamentous inclusions
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characteristic of MSA [47–49]. Until the early 2000s, αS fibrillization was thought to be a critical step
in the pathogenesis of α-synucleinopathies [2,50]. Subsequently, a change in secondary structure
from an unfolded random coil to an antiparallel β-sheet structure has been shown to accompany the
fibrillization of αS [51,52].
Comparable with the fibrillization of amyloid β-protein (Aβ) in vitro [53,54], the time course of
αS fibrillization fulfills all the criteria of the nucleation-dependent model, characterized by an initial
lag phase that reflects nucleation (seed formation) and a subsequent growth phase that culminates
in a steady state [55]. A conformational change in αS may result in the formation of misfolded
intermediates such as β-sheet oligomers or protofibrils (Figure 2) [55]. These αS aggregates can act as
the “seeds” in a nucleation-dependent model of αS fibrillization. A recent study revealed that αS fibrils
grow by monomer addition rather than oligomer addition and are subject to higher-order assembly
processes that decrease their capacity to grow [56]. It was also found that, at neutral pH, the growth of
αS aggregates and higher-order assembly of fibrils occur at much greater rates than either primary
nucleation or secondary processes. However, at mildly acidic pH values, secondary nucleation is
strongly accelerated, changing the mechanistic characteristics of αS aggregation. Thus, at mildly acidic
pH values—such as those, for example, that are present in some intracellular locations, including
endosomes and lysosomes—the multiplication of aggregates occurs much more quickly than at normal
physiological pH values, largely as a consequence of much more rapid secondary nucleation [56].
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Figure 2. αS mutants, including 46 , 53 , a 30 influence some stages of αS aggregation.
As with WT αS, the fibrillization of f llo s a nucleation-dependent model
dose-dependently [52,57–59]. S utants, including A53T, A30P, and E46K, have been reported
to influence some stages of αS aggregation in vitro (Figure 2) [46,49,57,58,60–62]. For example,
first, the A53T mutation increases the propensity for αS fibrillization, as well as the formation of
protofibrils [46,49,52]. Second, the A30P mutation promotes the formation of protofibrils but not αS
fibrils [52,60]. Some of these protofibrils, which have circular morphology, form pores by binding
to the endoplasmic reticulum membrane [13]. Third, the E46K mutation has also been reported to
increase the propensity for fibrillization in vitro [61] and to reduce the propensity for protofibrillization
by reducing the permeability of lipid vesicles [57]. In our previous in vitro study, E46K αS accelerated
the kinetics of the secondary structure changes and oligomerization, whereas A30P αS decelerated
these early changes compared with WT αS [58]. Similarly, the oligomers of E46K αS functioned as fibril
seeds significantly more efficiently than those of the WT αS, whereas the oligomers of A30P αS were
less efficient. These results demonstrated that αS mutations have opposite effects at the earliest stage
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of αS assembly [58]. Recently, a detailed analysis using X-ray diffraction pattern recording, circular
dichroism, Fourier-transform infrared spectroscopy, electron microscopy, and atomic force microscopy,
demonstrated that the subgrouping of different mutational variants from a kinetic perspective correlates
with the subgrouping of the structural and morphological features of the resulting fibrils. A53T and
A30P variants show similar kinetic constants, structure, and morphology, when compared with
the WT protein, whereas the E46K, H50Q, and G51D variants show large differences in secondary
structure, morphology, and microscopic steps in the aggregation mechanism, relative to the WT protein.
These results indicate that the mechanism underlying the amyloid formation, morphology, and structure
of fibrillar aggregates is generally correlated in all variants of αS. Thus, a single point mutation can
significantly alter the distribution of fibrillar polymorphs of αS, suggesting that differences in the
clinical phenotypes of familial PD could be associated with changes to the mechanism of formation
and the particular structural characteristics of the aggregates [59].
3. Toxicity of αS Oligomers
In vitro and in vivo studies support the oligomer hypothesis [12,17,52]. In vitro studies have
shown that annular protofibrils alter membrane permeability, resulting in an increased influx of
calcium from the extracellular to the intracellular space, leading to cell death [63,64]. Similarly,
annular low-n oligomers (mainly octamers) have been reported to form pore-like structures that
fully perforate the lipid layer of membranes with resultant calcium efflux; A53T αS shows a greater
tendency to establish this type of permeability than WT αS [65]. The study also demonstrated that
transgenic mice highly expressing αS E57K show abundant oligomeric, but not fibrillar, αS; exacerbated
synaptic and dendritic loss; diminished levels of synapsin 1 and synaptic vesicles; and behavioral
deficits. This suggests that accumulating αS oligomers may mediate early synaptic pathology in
α-synucleinopathies by disrupting synaptic vesicles [66]. Similarly, it has been shown, using the
brains of transgenic mice overexpressing αS and in a study of humans with LB dementia, that
αS oligomers are associated with the loss of several critical presynaptic proteins, which results
in dysfunctional synapses and eventual neurodegeneration [67]. Moreover, it has been reported
that oligomeric αS inhibits long-term potentiation through an increase in intracellular calcium
levels, induces calcineurin activity, reduces the cyclic AMP (adenosine monophosphate) response
element-binding protein transcriptional activity in ex vivo rat brain slices, and evokes memory
impairments in mice [14]. Recently, Knowles’s group used single-molecule techniques to measure
the equilibrium populations of oligomers formed in vitro by mixtures of WT αS and mutational αS
variants. They discovered that co-oligomer formation is generally more favorable than self-oligomer
formation at equilibrium [64]. Moreover, self-oligomers disrupt lipid membranes more potently
than do co-oligomers. However, this adverse effect can dominate when co-oligomers are present at
high steady state concentrations [64]. In 2019, Ghio et al. used single-channel electrophysiology to
observe that the presence of cardiolipin, the signature phospholipid in mitochondrial membranes,
enhances αS-lipid interaction and the membrane pore-forming activity of αS oligomers [68] (Figure 1).
Furthermore, they identified that the preincubation of isolated mitochondria with cardiolipin-specific
dye protects against αS oligomer-induced mitochondrial swelling and the release of cytochrome c.
This finding indicates that αS oligomers directly porate local lipid environments rich in cardiolipin,
such as outer mitochondrial contact sites or the inner mitochondrial membrane, to induce mitochondrial
dysfunction [68]. Similarly, Ahyayauch et al. revealed that the interaction between the Aβ
monomer and membrane becomes stronger in the presence of negatively charged cardiolipin using
both biophysical and computational techniques [69]. In 2020, McLean’s group demonstrated that
mitochondrial sirtuin 3 (SIRT3) downregulation is accompanied by decreased phosphorylation of
AMP-activated protein kinase (AMPK) and cAMP-response element-binding protein, as well as
increased phosphorylation of dynamin-related protein 1, which is indicative of impaired mitochondrial
dynamics in cells expressing oligomeric αS within the cytosolic and mitochondrial-enriched fractions.
Interestingly, treatment with the AMPK agonist 5-aminoimidazole-4-carboxamide-1-β-d-ribofuranoside
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restores SIRT3 expression, improves mitochondrial function, and decreases αS oligomer formation
SIRT3-dependently. These findings suggest that pharmacologically increasing SIRT3 levels can
counteract αS oligomer-induced mitochondrial dysfunction by reducing the number of αS oligomers
and normalizing mitochondrial bioenergetics [70]. Recently, Spillantini’s group interestingly showed
that treatment with the oligomer modulator anle138b restores striatal dopamine release and prevents
dopaminergic cell death and gait impairment in a new transgenic mouse line, MI2, which exhibits
progressive αS aggregation in dopaminergic neurons of the substantia nigra pars compacta and their
striatal terminals. These effects were associated with a reduction in the inner density of large αS
aggregates and an increase in dispersed small αS species, as revealed by dSTORM. These data provide
a new mechanistic insight into the effect of anle138b’s function in vivo, which supports the targeting of
αS oligomerization as a promising therapeutic approach for α-synucleinopathies [71].
4. Propagation of αS Aggregates Including Oligomers
α-Synuclein pathology exhibits an ascending distribution of the LB pathology in LB diseases,
as described by Braak, beginning in the lower brainstem and anterior olfactory nucleus, progressing to
midbrain and forebrain nuclei, and finally involving the cerebral cortex [2,72]. Cell-to-cell transfer and
seeding are other mechanisms by which αS pathology is suggested to propagate through the brain [73].
Notably, evidence includes the observation that healthy dopaminergic neurons transplanted into PD
brains can eventually form LBs [74–76]. This prion-like transmission of pathological seeds from host
cells to graft cells has been replicated in in vivo models [77,78].
Experimental evidence has repeatedly shown αS seeding to spread from the striatum to
dopaminergic neurons in the substantia nigra pars compacta, which innervates the striatum [79–81],
causing the death of these neurons [79,81] and resulting in a substantial reduction in striatal dopamine
levels and impaired motor coordination [79].
Another way in which αS resembles Aβ and tau is the existence of multiple conformational strains
with distinct biochemical properties and varying seeding effects and toxicity. Tau strains are also
essential for the seeding and propagation of tau pathology, and they target different brain regions [82].
Guo et al. demonstrated that two different strains of preformed αS fibrils can be generated, one of
which is highly effective at cross-seeding tau aggregation both in vitro in cultured cells and in vivo
in PS19 mice [83]. We previously examined whether sonicated fibrils or oligomers of αS, Aβ1–40,
and Aβ1–42 affected their aggregation pathways in vitro. These fibrils and oligomers acted as seeds and
affected the aggregation pathways within and among species, suggesting the possibility of molecular
interaction in propagation between the pathologies of α-synucleinopathies, Alzheimer’s disease, and
tauopathies [84]. Recently, Knowles’s group determined that co-oligomer formation of WT αS with
Aβ1–40, Aβ1–42, and tau is generally more favorable than self-oligomer formation at equilibrium
in vitro, suggesting that co-oligomer formation may also be important in the mixed pathologies of the
above-described neurodegenerative diseases [64].
α-Synuclein pathology becomes more severe with time and spreads to brain regions outside
the injection site after intracerebral seeding, as with seeded Aβ or tau pathology [85]. There is
strong evidence that the pattern of spread is dictated by connectivity [79,80] and is consistent with a
mechanism of anterograde and retrograde cell-to-cell transmission [86]. Evidence of trans-synaptic αS
propagation mediated by αS seeds crossing the synapse between first- and second-order neurons has
also been observed, with pathology appearing over time in regions indirectly connected to the injection
site [79,86,87]. Recent evidence suggests that toxic αS oligomers may be released from neurons via
unusual secretory mechanisms, such as exocytosis, in the pathogenesis of α-synucleinopathies [88,89].
Interestingly, these extracellular αS oligomers can then transfer between neurons or from neuron to glial
cells [90], where they can nucleate further intracellular aggregation, leading to neuroinflammation and
exacerbation of the neurodegenerative process [91,92]. The mechanisms through which extracellular
αS oligomers transfer to other cells include endocytosis [91,92], direct penetration [15], trans-synaptic
dissemination [93], and membrane receptor-mediated access [90]. Once inside the acceptor cell,
Molecules 2020, 25, 2444 7 of 19
αS oligomers can act as trigger points for further intracellular aggregation, or the protein can be targeted
for degradation. As discussed earlier, evidence from in vitro biophysical studies has consistently shown
that the fibrillization of αS follows a nucleated polymerization mechanism [51,55,58]. This mechanism
is characterized by a nucleation phase that initially involves the formation of oligomers (acting as
the seeds), followed by cooperative oligomer growth and fibrillization by monomer addition [84].
This process can be thought of as the mechanism that underlies the spread of αS pathology in the
brain (Figure 1). The process has been observed in a cell-based assay, in which the induction of
recombinant αS fibrils resulted in seeding, the recruitment of endogenous αS, and the formation
of LB-like inclusions [94]. A recent in vivo study has shown that the inoculation of αS transgenic
mice with homogenates containing αS protofibrils and fibrils results in a considerable enhancement
of αS pathology and propagation [80]. To directly visualize and characterize αS oligomerization
and spreading in vivo, Danzer’s group recently generated two independent conditional transgenic
mouse models, based on αS protein complementation assays, using neuron-specifically expressed split
Gaussia luciferase or split Venus yellow fluorescent protein (YFP) [95]. Using these mouse models, they
demonstrated the age-dependent accumulation of a specific subtype of αS oligomer in vivo. They also
provided in vivo evidence that, although αS is found throughout the neurons, αS oligomerization
occurs at the presynapse, and de novo generated αS oligomers are transferred via a trans-synaptic
cell-to-cell pathway in vivo [95] (Figure 1). These observations have led to the challenging hypothesis
that extracellular αS seeds may participate in the prion-like propagation of neurodegeneration in
α-synucleinopathies [12]. Further experimental evidence is needed to confirm this hypothesis.
5. Antioxidant Properties of Phenolic Compounds
Most polyphenols are salubrious because of their potent antioxidant nature. These agents can
neutralize free radicals via hydrogen atom abstraction [96]. Polyphenol transformation products with
free radicals produced by radical quenching can further react with secondary free radicals, leading to the
formation of a stable quinone structure [96]. Generally, their radical scavenging ability depends on the
molecular structure and substitution pattern of the hydroxyl group. Besides this ability, polyphenols can
also bind to metal ions, which may further enhance their antioxidant activity [96]. EGCG, an antioxidant
and metal-chelating polyphenol in green tea, was shown to regulate the iron-export protein ferroportin
in the substantia nigra, reduce oxidative stress (measured as protein carbonyls in serum), and finally
exert a neurorescue effect against MPTP-induced motor deficits in mice [28]. Similarly, Ryu et al.
screened HEK293 cells that stably express the microtubule-associated protein light chain 3 (LC3) protein,
a marker of autophagy, for autophagy activity in 100 single plant compounds, and identified amurensin
G, a compound isolated from the wild grape (Vitis amurensis) [97]. Treatment with amurensin G
induced the punctate cytoplasmic expression of green fluorescent protein (GFP)-LC3 and increased the
expression of endogenous LC3-II (Figure 1). The incubation of human dopaminergic SH-SY5Y cells
with amurensin G attenuated rotenone-induced cellular toxicities by reducing the level of ubiquitinated
proteins and αS. Moreover, amurensin G inhibited rotenone-induced apoptosis and interfered with
the rotenone-induced G2/M cell cycle arrest. With the added finding that the knockdown of beclin1,
a regulator of autophagy, abolished the effect of amurensin G, this compound was suggested to
attenuate neurotoxicity through the induction of autophagy in a cellular model of PD [97]. A botanical
extract prepared from grape (Vitis vinifera) and Polygonum cuspidatum, which contains polyphenols
(including flavans, anthocyanins, emodin, and resveratrol), exhibited dose-dependent scavenging
effects on ROS (Figure 1). The extract inhibited increases in ROS and protein carbonyl in isolated rat
liver mitochondria following exposure to 2,2′-azobis (2-amidino propane) dihydrochloride (AAPH),
a potent lipid oxidant generator. The antioxidant effects of this extract were further demonstrated by
protecting the enzyme activities of the mitochondrial respiratory electron transport chain (complexes I
and II) and pyruvate dehydrogenase in isolated liver mitochondria with AAPH insult. The pretreatment
of human neuroblastoma cells (SKN-MC) with extract induced oxidation to maintain cell viability
while inhibiting excessive ROS generation. The extract was also fed to transgenic human αS-expressing
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Drosophila models that produce adult-onset loss of dopaminergic neurons, filamentous intraneuronal
inclusions containing αS, and locomotor dysfunction. Male transgenic flies fed with the extract
showed a significant improvement in climbing ability, compared with controls, using a geotaxis assay.
Furthermore, female transgenic flies showed a significant extension in average lifespan. Similarly,
the consumption of grape skin extract containing resveratrol was reported to result in the rescue of
mitochondrial morphological defects, improvement of indirect flight muscle function and healthspan,
and prolonged lifespan in a Drosophila melanogaster model of PD associated with phosphatase tensin
homolog-induced kinase 1 loss of function [98]. These results suggest that botanical extracts containing
a variety of polyphenols are potent free radical scavengers and mitochondrial protectors that protect
against neurodegeneration and potentially extend lifespan in a PD model [99].
6. Inhibition of αS Fibrillization by Phenolic Compounds
Over the last two decades, various phenolic compounds have been tested extensively for their
ability to inhibit αS aggregation. It has been clearly shown that certain polyphenols can dramatically
inhibit cell death induced by αS aggregates [100–102]. To assist in developing a disease-modifying
approach for α-synucleinopathies focused on the aggregation of αS, our group and others have
reported that various phenolic compounds such as wine-related polyphenol [27,32], NDGA [27],
rifampicin [103], and Cur [27] inhibitαS fibrillization and destabilize preformed fibrils. In our first study
of αS, compounds with anti-fibrillogenic and fibril-destabilizing activity were ranked in the following
order: tannic acid = NDGA = Cur = RA = Myr > kaempferol = FA > (+)-catechin = (–)-epicatechin
> rifampicin = tetracycline [27]. NDGA, Cur, and RA are smaller than rifampicin and have two
3,4-dihydroxyphenyl rings (NDGA and RA) or 4-hydroxy-3-methoxyphenyl rings (Cur) symmetrically
bound by a short hydrocarbon chain. Similarly, FA contains one 4-hydroxy-3-methoxyphenyl ring
and has been identified as a degradation product of Cur [104]. This compact structure may be quite
suited specifically to binding free αS monomers and, subsequently, inhibiting the polymerization
of peptides into fibrils. Alternatively, this structure might be suited to binding preformed fibrils of
αS and, subsequently, destabilizing the β-sheet rich conformation of these molecules in fibrils [27].
We speculated that the difference in the three-dimensional structure and the numbers of hydroxyl
groups of these phenolic compounds would greatly affect binding to αS monomers and/or αS fibrils in
anti-aggregation and fibril-destabilizing activity (Ono et al. 2006). Another systematic study showed
that polyphenols such as Cur, baicalein, EGCG, and resveratrol in combination with β-cyclodextrin not
only synergistically inhibited αS aggregation but were also effective in disaggregating preformed fibrils
at substoichiometric concentrations of the individual components, resulting in the reduced toxicity
of prefibrillar αS aggregates on mouse neuroblastoma cell lines (N2a cells) [105]. In recent work,
EGCG was shown to form a Cu(II)/EGCG complex, leading to the inhibition of the Cu(II)-induced
conformation transition of αS from random coil to β-sheet, which is a dominant structure in αS fibrils
and aggregates [106]. Moreover, the mixture of Cu(II) and EGCG in a molar ratio from 0.5 to 2 efficiently
inhibited this process. Furthermore, EGCG inhibited the overexpression and fibrillization of αS in
αS-transduced PC12 cells and reduced Cu(II)-induced ROS, protecting the cells against Cu(II)-mediated
toxicity [106]. Cur was found to be the most efficient of the polyphenols investigated, followed by
baicalein, EGCG, and resveratrol, with the latter two compounds exhibiting very similar effects.
The authors suggested that the efficiency of Cur results from a balanced composition of the phenolic
OH groups, benzene rings, and flexibility. The latter ensures the proper positioning of the functional
groups to maximize underlying interactions with both the monomer of αS and its aggregates [105].
Fink’s group (2004) previously reported that, at low micromolar concentrations, baicalein not
only inhibits αS fibrillization but also disaggregates preformed αS fibrils [32]. They suggested
that the product of the inhibition reaction is predominantly a soluble oligomer of αS, in which the
protein molecules have been covalently modified by the binding of baicalein quinone to form a
Schiff base with a lysine side chain in αS [32]. Similarly, Li et al. (2004) showed that rifampicin,
having a phenolic structure, also inhibits αS fibril formation at substoichiometric low micromolar
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concentrations and disaggregates preformed αS fibrils by covalent binding to stabilize αS monomers
and oligomers on the off-pathway [103]. Similarly, Ehrnhoefer et al. (2008) reported that EGCG
efficiently inhibitsαS fibrillization by stabilizing non-toxic oligomers on the off-pathway differently from
those on the on-pathway, through the direct binding of the unfolded monomer [33,34]. More recently,
EGCG-mediated protection againstαS oligomers has been reported to reduce membrane disruption and
subsequent cellular degeneration by facilitating the conversion of on-pathway toxic αS oligomers into
fibrils and thus accelerating the removal of toxic oligomers [35]. Furthermore, Xu et al. demonstrated
that EGCG inhibits αS aggregation concentration-dependently using three methods: αS fibril formation
inhibition by thioflavin T binding in vitro, inhibition of αS fluorophore αS-HiLyte488 binding to
plated αS in a microplate assay, and inhibition of αS -HiLyte488 probe binding to aggregated αS
in a post-mortem PD tissue-based assay [107]. The αS amino acid sites, which potentially interact
with EGCG, were detected on peptide membranes, implying that EGCG binds to αS through instable
hydrophobic interactions [107]. El-Agnaf’s group showed that gallic acid (GA, 3,4,5-trihydroxybenzoic
acid), a benzoic acid derivative that belongs to a group of phenolic compounds known as phenolic acids,
not only inhibits αS fibrillization and toxicity but also disaggregates preformed αS fibrils. Interestingly,
GA was also found to bind to soluble, non-toxic oligomers with no β-sheet content and to stabilize their
structure [101]. The structure activity relationship data obtained from 14 structurally similar benzoic
acid derivatives demonstrated that the inhibition of αS fibrillization by GA is related to the number
of hydroxyl moieties and their position on the phenyl ring, which concurs with our data [27,101].
Macedo et al. evaluated the effects of a polyphenol-enriched fraction (PEF) from the leaves of Corema
album on αS toxicity and aggregation in vitro and using αS-expressing cellular models. The PEF
promoted the formation of non-toxic αS oligomers in vitro and inhibited αS toxicity and fibrillization
in cells by stimulating autophagy and reducing oxidative stressors such as H2O2 [102].
In animal models of PD, several studies have clearly demonstrated that various phenolic
compounds possess neuroprotective effects, but no study has investigated the interaction between
polyphenols and αS aggregation in vivo [108]. Using transgenic mice with overexpressed human
GFP-tagged WT αS, a Cur-containing diet was shown to improve motor behavior with an increase in
phosphorylated αS, but no effect on αS aggregation was seen in vivo [109].
7. Inhibition of αS Oligomerization by Phenolic Compounds
In relation to the oligomer hypothesis for the pathogenesis of α-synucleinopathies, we and
other groups showed that phenolic compounds inhibit αS oligomerization and reduce cytotoxicity
in vitro and in vivo. Cur, the main component of turmeric spice, was reported to both inhibit and
reverse the formation of high-order toxic αS oligomers by directly binding to αS in vitro and in cell
culture models [110]. Subsequently, Cur was demonstrated to intra- and extra-cellularly alleviate
αS oligomer-induced toxicity by reducing the levels of ROS and inducing apoptosis in SH-SY5Y
cells [111]. Using a series of biophysical techniques, Maji’s group demonstrated that Cur reduces
toxicity by binding to αS oligomers and fibrils on-pathway, and that reducing the solvent exposed their
hydrophobic surface [112]. Their fluorescence and two-dimensional nuclear magnetic resonance (NMR)
data indicated that Cur does not bind to monomeric αS but instead binds specifically to oligomeric
intermediates. The degree of Cur binding correlates with the extent of αS oligomerization suggests that
an ordered protein structure is required for effective Cur binding. The acceleration of αS aggregation
by less toxic off-pathway oligomers altered by Cur may decrease the population of toxic αS oligomers
on-pathway [112]. Later, using biochemical, biophysical, and cell-based assays, it was discovered that
Cur pyrazole and its derivative N-(3-nitrophenylpyrazole) Cur exhibit remarkable potency in not only
inhibiting fibrillization and disrupting preformed αS fibrils but also preventing the formation of A11
reactive αS oligomers that impart toxic effects by promoting stabilization of off-pathway oligomers.
The compounds also decreased the neurotoxicity associated with fast aggregating A53T αS in SH-SY5Y
cells [113].
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Recently, resveratrol was found to inhibit αS aggregation in vitro and reduce αS oligomer-induced
cytotoxicity in SH-SY5Y cells, while alleviating motor and cognitive deficits in the A53T αS mouse
model of PD, by lowering the levels of total αS and oligomers; reducing neuroinflammatory cytokines
such as tumor necrosis factor-α, interleukin (IL)-1β, and IL-6; and limiting oxidative stress factors such
as ROS and malondialdehyde in vivo.
Using methods such as the photo-induced cross-linking of unmodified proteins (PICUP), circular
dichroism spectroscopy, electron microscopy, and atomic force microscopy, we previously reported that,
dose-dependently, Myr and RA inhibit a low-n order oligomerization and secondary structure transition
of αS including random coil→ β-sheet [114]. Similarly, the polymeric wine-related polyphenol, tannic
acid, was reported to display inhibitory effects on αS oligomerization and disaggregate preformed αS
oligomers in vitro [115]. Our detailed NMR-based investigation revealed that Myr directly binds to the
N-terminal region ofαS, whereas direct binding of RA to monomericαS was not detected. More recently,
quercetin was also shown to bind monomeric αS covalently, with the increased hydrophilicity of the
covalently modified αS resulting in the inhibition of further aggregation [116]. Moreover, by recording
long-term potentiation in mouse hippocampal slices, our electrophysiological assays demonstrated that
these phenolic compounds reduce the synaptic toxicities of αS oligomers [114]. We previously reported
similar inhibitory effects of Myr and RA on Aβ oligomerization, resulting in the reduction of Aβ
oligomer-induced cellular toxicity and synaptic dysfunction in vitro and in vivo [117,118]. Our NMR
analysis of Aβ also showed a similar result in that Myr promoted significant NMR chemical shift
changes of monomeric Aβ. These results suggest that phenolic acids may play key roles in blocking
the toxicity and early assembly processes associated with both αS and Aβ through different binding
strategies [114,118].
Our group demonstrated that rifampicin, with its phenolic structure, inhibits the low-n order
oligomerization of Aβ, tau, and αS with the reduction of synapse loss and microglial activation in vitro
and in vivo. The intake of rifampicin improved the memory of the mice to a level similar to that in
non-transgenic littermates in the Morris water maze. Rifampicin also inhibited cytochrome c release
from mitochondria and caspase-3 activation in the hippocampus. Moreover, rifampicin decreased
the level of p62/sequestosome-1 in the brain without affecting the increased levels of LC3 conversion,
suggesting the restoration of autophagy-lysosomal function (Figure 1). These studies collectively
indicate that rifampicin has a broad spectrum of effects and can be used in various pathologies related
to oligomers, that is, Alzheimer’s disease, tauopathy, and α-synucleinopathies [119]. Conversely,
recent randomized, double-blind, placebo-controlled clinical trial studies have shown that rifampicin
and EGCG fail to prevent disease progression in patients with progressive Alzheimer’s disease [120]
or with possible or probable MSA [121,122]. Future studies should evaluate rifampicin and other
phenolic compounds with anti-oligomeric effects for the early presymptomatic stage (the oligomer
phase) of neurodegenerative diseases including α-synucleinopathies.
8. Gut Microbiome-Modified Polyphenolic Compounds Inhibit αS Seeding and Spreading in
α-Synucleinopathies
The intestinal microbiota actively converts dietary polyphenols into phenolic acids, some of which
are bioavailable in vivo and may promote resilience to select neurological disorders by interfering
with key pathologic mechanisms. Since every person harbors a variety of gut bacteria, we previously
investigated the influence of the gut microbiota’s interpersonal heterogeneity on the production
and bioavailability of polyphenol metabolites that may interfere with αS misfolding. In the study,
we generated two experimental groups of humanized gnotobiotic mice with compositionally diverse
gut bacteria and orally treated the mice with a polyphenol-rich preparation. The two gnotobiotic
mouse groups exhibited distinct differences in the generation and bioavailability of phenol metabolites
that show bioactivity in disrupting αS aggregation or reducing inflammation.
We found 15 polyphenol-derived microbial phenolic acid metabolites, including caffeic acid,
FA, GA, and vanillic acid at µM to sub-µM concentrations in the cecal compartment across the two
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gnotobiotic mouse groups. Between the two mouse groups, the breakdown of these metabolites,
detected not only in the cecum, colon, and plasma but also in the brain, was different, suggesting
that interpersonal heterogeneity in human gut microbiota can drive significant differences in the
bioavailability of polyphenol-derived microbial phenolic metabolites in gnotobiotic mice. Three of
the 15 biologically available polyphenol-derived metabolites identified in the cecum specimens of
gnotobiotic mice, namely, 3,4-diHBA, 3-HBA, and 3-HPPA, accumulate in the brain, although 12
phenolic acid metabolites were detected in plasma specimens from the mice [43]. As with our previous
report that 3-HBA and 3-HPPA are effective in preventing the misfolding and assembly of Aβ peptides
into neurotoxic aggregates such as Aβ oligomers [123], we showed that 3-HBA, 3,4-diHBA, and 3-HPPA
inhibit αS aggregation, including the formation of low-order oligomers such as dimers and trimers,
using combination assays with thioflavin dye, electron microscopy, and PICUP. Using the A53T mutant
αS Drosophila model of PD, we further investigated the effects of 3-HBA, 3,4-diHBA, and 3-HPPA on
modulating PD pathologic phenotypes, in vivo, by monitoring locomotive functions using a negative
geotaxis behavior assay (climbing assay) in adult flies [124]. We demonstrated that, in comparison
with vehicle-treated mutant flies showing locomotive dysfunction, treatment with 3-HBA, 3,4-diHBA,
and 3-HPPA significantly improved the climbing performance of mutant αS-expressing flies [43]. Thus,
not only do 3-HBA, 3,4-diHBA, and 3-HPPA reduce the assembly of αS into neurotoxic aggregates
in vitro, but these compounds also reduce mutant αS-mediated neurotoxicity in vivo [43]. Very recently,
we investigated whether or not 3-HBA, 4-HBA, 3,4-diHBA, or 3-HPPA interfere with αS spreading,
in a cell-based system. Using HEK293 cells overexpressing αS-A53T-cyan FP/YFP, we assessed αS
seeding activity using Fluorescence Resonance Energy Transfer to detect and quantify αS aggregation.
Consequently, we demonstrated that 3-HPPA, 3,4-diHBA, 3-HBA, and 4-HBA significantly attenuate
cell-to-cell transfer and intracellular αS seeding aggregation [44] (Figure 1). To determine whether our
compounds could inhibit brain-derived seeding activity, we used insoluble αS aggregates extracted
from post-mortem MSA or PD brain specimens. We found that 3-HPPA effectively attenuates the
MSA-induced aggregation of monomers into high molecular weight aggregates capable of inducing the
intracellular aggregation of αS [44]. The outcomes of our studies suggest that the interactions between
the gut microbiome and certain phenolic compounds may be effective therapies for modulating
pathologic αS aggregation and propagation.
9. Conclusions and Future Perspectives
αS aggregation is one of the leading causes of neuronal dysfunction and death in
α-synucleinopathies. Current therapies for α-synucleinopathies are limited to symptomatic therapies.
The modulation of αS aggregation is emerging as a novel therapeutic target for the treatment of
PD. There are two major aspects of αS aggregation that might be targeted therapeutically: first,
the protein is prone to aggregate; therefore, anti-aggregative compounds or those that can break
pre-existing aggregates may be helpful. Second, there are a number of molecular events, such as
aggregation propagation or accumulation of aggregates, that may be targeted therapeutically. There is
growing evidence that intermediate aggregates, the soluble oligomers of αS, are proximate neurotoxins.
Dietary polyphenols and bioactive metabolites produced by intestinal microbiota are effective not
only in the misfolding, oligomerization, and propagation of αS in vitro and in cellular models but
also in modulating the development and progression of motor dysfunction in an in vivo model of
α-synucleinopathy. If phenolic compounds that target the formation and propagation of toxic αS
oligomers reach the clinical stage of investigation in the near future, they have the potential to delay
the progression of PD and other α-synucleinopathies. Further clarification of the anti-aggregation
effects on αS in the human brain will assist in the development of more effective and safer therapeutics,
as well as novel diagnostic assays for α-synucleinopathies.
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Abbreviations
AAPH 2,2′-azobis (2-amidino propane) dihydrochloride
Aβ amyloid β-protein
AMP adenosine monophosphate
AMPK AMP-activated protein kinase
αS α-synuclein
Cur curcumin
3,4-diHBA 3,4-dihydroxybenzoic acid
DLB dementia with Lewy bodies
EGCG (–)-epigallocatechin gallate
FA ferulic acid
GA gallic acid
GFP green fluorescent protein
3-HBA 3-hydroxybenzoic acid
4-HBA 4-hydroxybenzoic acid
HEK human embryonic kidney
3-HPPA 3-hydroxyphenylacetic acid
IL interleukin
LB Lewy body
LC3 microtubule-associated protein light chain 3
MPTP 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
MSA multiple system atrophy
mTOR mammalian target of rapamycin
Myr myricetin
NDGA nordihydroguaiaretic acid
NMR nuclear magnetic resonance
PD Parkinson’s disease
PEF polyphenol-enriched fraction
PICUP photo-induced cross-linking of unmodified proteins
RA rosmarinic acid
ROS reactive oxygen species
SIRT sirtuin 3
WT wild-type
YFP yellow fluorescent protein
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